Last reviewed · How we verify
Stable doses of anti-TNF
At a glance
| Generic name | Stable doses of anti-TNF |
|---|---|
| Also known as | Adalimumab: 40 mg / 2 weeks, Etanercept: 25 mg / 3 days ó 50 mg /7 days, Golimumab: 50 mg / 4 weeks, Infliximab: 5 mg/kg / 6-8 weeks |
| Sponsor | Spanish Clinical Pharmacology Society |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis (PHASE3)
- Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis (PHASE4)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010) (PHASE2)
- Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
- A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy (PHASE2)
- A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (PHASE3)
- Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study (PHASE4)
- A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stable doses of anti-TNF CI brief — competitive landscape report
- Stable doses of anti-TNF updates RSS · CI watch RSS
- Spanish Clinical Pharmacology Society portfolio CI